Support Pullquote, upgrade to Pro!
(Or just tweet your Pullquote for free!)
With Pullquote Pro, you'll get to:
- share on Facebook
- schedule tweets
- tweet from multiple accounts
- edit quotes
- customize colors
- change fonts
- save and index quotes
- private quotes
Choose a plan: $5/month $50/year (includes free access to any new features)
Recent quotes:
Why Does Duke Have So Few Low-Income Students? - The New York Times
An earlier study by the Opportunity Insights researchers, based on data from the early 2010s, came to a shocking conclusion: Dozens of colleges, including Duke, enrolled more students from the top 1 percent of the income distribution than from the entire bottom 60 percent. The same appears to be true of the most recent graduating classes at Duke.
Why Does Duke Have So Few Low-Income Students? - The New York Times
Compared with other universities, Duke has not enrolled many low-income students. A recent academic study of 12 elite colleges — the eight in the Ivy League, as well as Duke, Stanford, the Massachusetts Institute of Technology and the University of Chicago — found that Duke gave some of the largest advantages in the admission process to students from families making at least $250,000 a year. Only about 12 percent of Duke students in recent years have received Pell Grants, the largest federal scholarship program, which is typically available to families in the lower half of the income distribution, earning $60,000 a year or less. By comparison, the Pell shares at Harvard, Yale, Princeton, M.I.T. and Columbia have each recently hovered around 20 percent. Federal data suggests that Duke also has fewer middle-income students, coming from families that earn too much to qualify for Pell Grants but still less than $100,000 a year. The difference between Duke and its peers amounts to several hundred lower- and middle-income students who have been missing from its campus every year.
Can the US Dodge a Recession? This Economist Thinks So - Bloomberg
“In science we use models all the time, and they’re simplifications of reality,” he said. “And part of the skill of the scientist is to know when to deploy the model and when not to or, in other words, to know the limitations of the model. And maybe I’m in a good position of knowing the limitations, given that it’s my model.”
Statistical considerations for rare diseases drug development. - PubMed - NCBI
One of the most challenges for rare disease clinical trials is probably the availability of a small patient population. It is then a great concern on how to conduct clinical trials with a small number of subjects available for obtaining substantial evidence regarding safety and effectiveness for approval of the rare disease drug product under investigation. FDA, however, does not have the intention to create a statutory standard for approval of orphan drugs that are different from the standard for approval of drugs in common conditions. Thus, it is suggested that innovative trial designs such as a complete n-of-1 trial design or an adaptive design should be used for an accurate and reliable assessment of rare disease drug products under investigation. In this article, basic considerations, innovative trial designs, and statistical methods for data analysis are discussed. In addition, some innovative thinking for the evaluation of rare disease drug products is proposed.
